Neuropathix

Pharmaceutical Manufacturing • Buckingham, Pennsylvania, United States • 1-10 Employees

Company overview

Headquarters	3805 Old Easton Road, Doylestown, PA 18902, US
Phone number	+12156956559
Website	neuropathix.com
NAICS	3254
SIC	283
Employees	1-10
Socials

Key Contact at Neuropathix

Dean Petkanas

Chief Executive Officer

About Neuropathix

Neuropathix, Inc. is a pioneering biopharmaceutical company advancing globally patented, synthetic cannabinoid-inspired therapeutics for the treatment of neurodegenerative and neuropathic diseases. Headquartered at the Pennsylvania Biotechnology Center with its wholly owned subsidiary Kannalife Sciences, Inc., it’s lead drug candidate, KLS-13019, targets key drivers of neuroinflammation and mitochondrial dysfunction, including mNCX-1, GPR55, and the NLRP3 inflammasome. The company’s innovation has been recognized through substantial non-dilutive funding, including a $1.5 million grant from The Michael J. Fox Foundation for Parkinson’s Research and $3.3 million from the NIH HEAL Initiative to support IND-enabling studies to advance KLS-13019 toward clinical trials.

Neuropathix revenue & valuation

Annual revenue	$256,665
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$821,328
Total funding	No funding